Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Common Equity (2020 - 2026)

Journey Medical filings provide 6 years of Common Equity readings, the most recent being $31.9 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 58.71% to $31.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $31.9 million, a 58.71% increase, with the full-year FY2025 number at $31.9 million, up 58.71% from a year prior.
  • Common Equity hit $31.9 million in Q4 2025 for Journey Medical, up from $25.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $42.0 million in Q4 2021 to a low of -$11.7 million in Q3 2021.
  • Median Common Equity over the past 5 years was $18.3 million (2023), compared with a mean of $17.9 million.
  • Biggest five-year swings in Common Equity: crashed 271.61% in 2021 and later surged 225800.0% in 2024.
  • Journey Medical's Common Equity stood at $42.0 million in 2021, then crashed by 59.61% to $17.0 million in 2022, then increased by 19.83% to $20.3 million in 2023, then decreased by 1.38% to $20.1 million in 2024, then surged by 58.71% to $31.9 million in 2025.
  • The last three reported values for Common Equity were $31.9 million (Q4 2025), $25.9 million (Q3 2025), and $19.2 million (Q2 2025) per Business Quant data.